TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.

Scott R Plotkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.